Kura Oncology Inc. (KURA) and bluebird bio Inc. (NASDAQ:BLUE) Contrasting side by side

Both Kura Oncology Inc. (NASDAQ:KURA) and bluebird bio Inc. (NASDAQ:BLUE) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology Inc. N/A 0.00 60.45M -1.67 0.00
bluebird bio Inc. 54.58M 159.12 555.63M -10.67 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Kura Oncology Inc. and bluebird bio Inc.

Profitability

Table 2 has Kura Oncology Inc. and bluebird bio Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Kura Oncology Inc. 0.00% -44.8% -39.5%
bluebird bio Inc. -1,018.01% -32.1% -27%

Risk and Volatility

A 2.91 beta indicates that Kura Oncology Inc. is 191.00% more volatile compared to Standard & Poor’s 500. Competitively, bluebird bio Inc.’s beta is 2.65 which is 165.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Kura Oncology Inc. are 14.8 and 14.8 respectively. Its competitor bluebird bio Inc.’s Current Ratio is 9.7 and its Quick Ratio is 9.7. Kura Oncology Inc. can pay off short and long-term obligations better than bluebird bio Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Kura Oncology Inc. and bluebird bio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kura Oncology Inc. 0 0 0 0.00
bluebird bio Inc. 0 3 6 2.67

Meanwhile, bluebird bio Inc.’s average target price is $154.78, while its potential downside is -2.06%.

Institutional & Insider Ownership

The shares of both Kura Oncology Inc. and bluebird bio Inc. are owned by institutional investors at 84% and 0% respectively. Insiders owned roughly 11.7% of Kura Oncology Inc.’s shares. Comparatively, insiders own roughly 0.7% of bluebird bio Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kura Oncology Inc. -2.2% -5.16% 22.4% -20.84% -32.98% 7.41%
bluebird bio Inc. 1.95% 14.54% 25.54% -10.57% -24.77% 54.06%

For the past year Kura Oncology Inc.’s stock price has smaller growth than bluebird bio Inc.

Summary

bluebird bio Inc. beats on 6 of the 10 factors Kura Oncology Inc.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.